APELOA's subsidiary has obtained the drug registration certificate for L-carnitine injection
APELOA's subsidiary, Zhejiang Puluo Kangyu Pharmaceutical Co., Ltd., has obtained the drug registration certificate for L-Carnitine Injection issued by the National Medical Products Administration. This drug is suitable for complications in patients with chronic renal failure, with an expected market size of 103 million units and sales amounting to 965 million yuan in China's hospital market in 2024. To date, the cumulative research and development expenses amount to 3.7629 million yuan
According to the Zhitong Finance APP, APELOA (000739.SZ) announced that its holding subsidiary, Zhejiang Puluo Kangyu Pharmaceutical Co., Ltd., has received the "Drug Registration Certificate" for L-carnitine injection issued by the National Medical Products Administration.
This drug is suitable for a series of complications caused by secondary carnitine deficiency in patients with chronic renal failure undergoing long-term hemodialysis, with clinical manifestations such as cardiomyopathy, skeletal myopathy, arrhythmia, hyperlipidemia, as well as hypotension and muscle cramps during dialysis. According to relevant data, the market size of L-carnitine injection in China's hospital market for the year 2024 is estimated to be 103 million doses, with sales amounting to 965 million yuan. As of the date of this announcement, the cumulative research and development expenses for L-carnitine injection have reached 3.7629 million yuan
